Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A
recombinant monoclonal antibody used to targettumour cells .
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word adecatumumab.
Examples
-
The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors.
unknown title 2009
-
May 29 to June 5, 2009: Update on a phase 1b clinical trial combining adecatumumab with docetaxel in late stage metastatic breast cancer patients at the annual meeting of the American Society for Clinical Oncology (ASCO) in Orlando, FL.
unknown title 2009
-
-- In September, Micromet presented the first clinical data from a phase 1b clinical trial studying the combination of adecatumumab with docetaxel in late stage metastatic breast cancer patients at the European Society for Medical Oncology in Stockholm, Sweden.
GEN News Highlights 2009
-
Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer.
unknown title 2009
-
Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer.
News 2009
-
-- In the first half of 2009, we expect to initiate a randomized, controlled, multicenter phase 2 clinical trial for relapsed colorectal cancer patients after complete resection of liver metastasis with adecatumumab, an EpCAM-targeting human monoclonal antibody that we develop in collaboration with Merck Serono; -- Before the end of 2009, we plan to initiate an additional phase 2 clinical trial in patients with non-Hodgkin's lymphoma with blinatumomab.
GEN News Highlights 2009
-
The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors.
GEN News Highlights 2009
-
Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer.
GEN News Highlights 2009
-
-- May 29 to June 5, 2009: Update on a phase 1b clinical trial combining adecatumumab with docetaxel in late stage metastatic breast cancer patients at the annual meeting of the American Society for Clinical Oncology (ASCO) in Orlando, FL.
GEN News Highlights 2009
-
The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors.
News 2009
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.